Author Affiliations: Research Center, Centre of Excellence in Neuromics of Université de Montréal Centre Hospitalier de l’Université de Montréal (CHUM) (Ms Belzil and Drs Daoud, Dion, and Rouleau); Departments of Pathology and Cellular Biology (Dr Dion) and Medicine, Faculty of Medicine (Dr Rouleau), Université de Montreal; and the Research Center, Centre Hospitalier Universitaire Sainte-Justine (Dr Rouleau), Montreal, Quebec, Canada.
Amyotrophic lateral sclerosis (ALS) is characterized by a neuronal loss in the motor cortex, brainstem, and spinal cord that progresses over a 3 to 5 year period. Approximately 90% of cases are considered sporadic, while the other 10% of cases are familial.1 Extensive research has been conducted on the SOD1 (RefSeq NM_000454.4) gene after mutations were identified more than 17 years ago in 15% to 20% of familial ALS cases, as well as a small number of sporadic ALS cases in later reports.1 In the last 2 years, mutations in TARDBP, which encodes TAR DNA-binding protein 43 (TDP-43), and in FUS have been identified in both familial and sporadic ALS cases.2- 4 Both genes encode for RNA/DNA binding proteins, are mainly localized in the nucleus, and are implicated in the regulation of RNA processing.5 Specifically, TDP-43 and FUS have been shown to be associated with other splicing factors and are believed to play a role in splicing regulation, as variation in their expression level influences the splicing of certain targets.5 Interestingly, mutant TDP-43 proteins identified in patients with ALS were recently reported to be more stable than wild-type TDP-43 and to display an enhanced interaction with fused in sarcoma (FUS) polypeptides.6 Particularly, it was reported that the FUS protein interacts more predominantly with mutant TDP-43, which display an increased half-life compared with wild-type TDP-43. The authors concluded on a note about the efforts needed to determine whether the increased association affects the RNA targets for TDP-43, FUS/translocated in liposarcoma protein, or both.6 Considering that abnormal RNA processing and splicing patterns are involved in neurodegenerative diseases1 and that variation in the RNA splicing of SOD1 can cause familial ALS by destabilizing the resulting protein,1 our aim was to assess if TARDBP and/or FUS ALS-predisposing mutations that are known to lead to the accumulation of TDP-43 or FUS aggregations in the cytoplasm also lead to aberrant SOD1 RNA splicing events, and to determine if SOD1 could be an RNA target for TDP-43, FUS, or both.
We studied total RNA prepared from immortalized lymphoblastoid cells of 1 healthy control individual as well as 7 participants with different TARDBP mutations (p.D169G, p.G287S, p.G348C, p.R361S, p.Y374X, p.A382T, p.N390D) and 4 participants with different FUS mutations (p.P18S, p.G174del, c.1542-2A>C, p.R521H). Protocols were approved by the ethics committee and the institutional review board of the University of Montreal. All patients gave written informed consent, after which patient information and blood were collected. The RNA was extracted using standard conditions. Reverse-transcription polymerase chain reactions were conducted using prepared complement DNA and the Moloney murine leukemia virus reverse transcriptase enzyme (Invitrogen, Carlsbad, California) per the manufacturer's instructions. The amplifications were performed using 2 sets of primer pairs that covered the entire messenger RNA of SOD1. Polymerase chain reaction products were sequenced at the Genome Quebec Innovation Centre (Montréal, Québec, Canada) using a 3730XL DNA analyzer (Applied Biosystems, Carlsbad, California). The first set amplified a region of 423 base pairs (bp) (c.1-439), starting at the beginning of the 5′ untranslated region and ending at the beginning of exon 4. The second set of primers amplified a product of 528 bp (c.398-462), starting at the beginning of exon 4 and ending at the end of the 3′ untranslated region.
Agarose gel electrophoresis showed that only 1 product was amplified for each of the complement DNA amplified (Figure). In addition, no variation was found in the sequence traces of the SOD1 complement DNA products.
Agarose gel electrophoresis of SOD1 messenger RNA. The first amplified product of 423 base pairs (bp) for the control and the 11 TARDBP or FUS mutants is shown on top. The second product of 528 bp is shown under the first product for the same samples.
We can conclude that TARDBP or FUS ALS-predisposing mutations do not affect the splicing of SOD1 and that, while it can't be excluded that there may be a common ALS pathogenic pathway, it appears that mutant TARDBP and FUS do not act by affecting the splicing of the most frequently mutated gene, SOD1, in ALS.
Correspondence: Dr Rouleau, CHUM Research Centre, Notre-Dame Hospital, 1560 Sherbrooke E, Y-3633, Montreal, QC H2L 4M1, Canada (firstname.lastname@example.org).
Author Contributions:Study concept and design: Belzil, Dion, and Rouleau. Acquisition of data: Daoud. Analysis and interpretation of data: Belzil, Daoud, and Dion. Drafting of the manuscript: Belzil. Critical revision of the manuscript for important intellectual content: Belzil, Daoud, Dion, and Rouleau. Obtained funding: Rouleau. Administrative, technical, and material support: Belzil, Daoud, and Dion. Study supervision: Dion and Rouleau.
Financial Disclosure: None reported.
Funding/Support: This study was supported by the Canadian Institutes of Health Research (Ms Belzil and Drs Daoud and Rouleau).
Additional Contributions: We would like to thank the patients involved in this study.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.